Table 3. Risks of outcomes among immunocompromised patients after inverse probability of treatment weighting.
| Outcomes | Unadjusted OR | p-value | Adjusted OR* | p-value |
|---|---|---|---|---|
| (95% CI) | (95% CI) | |||
| In-hospital mortality | 3.40 (2.71–4.26) | < .001 | 2.09 (1.62–2.68) | < .001 |
| Conventional oxygen therapy | 1.74 (1.56–1.94) | < .001 | 1.19 (1.05–1.35) | 0.007 |
| High flow nasal cannula | 2.44 (1.94–3.07) | < .001 | 1.28 (1.00–1.65) | 0.055 |
| Mechanical ventilation | 2.04 (1.52–2.73) | < .001 | 1.06 (1.05–1.07) | 0.018 |
| ECMO | 2.17 (1.04–4.51) | 0.038 | 2.17 (1.02–4.63) | 0.045 |
| Vasopressor use | 2.01 (1.56–2.59) | < .001 | 1.04 (0.79–1.38) | 0.773 |
| Renal replacement therapy | 2.48 (1.25–4.91) | 0.010 | 1.26 (0.61–2.63) | 0.534 |
| Acute heart failure | 1.76 (1.51–2.05) | < .001 | 1.39 (1.18–1.64) | < .001 |
IPTW: Inverse probability of treatment weighting; OR: Odds ratio; CI: Confidence interval; ECMO: Extracorporeal membrane oxygenation.
* Adjusted for Charlson Comorbidity Index, age, and region.